SRGA - Surgalign stock rises 7% after receiving FDA clearance of Cortera spinal fixation system
- Surgalign Holdings ( NASDAQ: SRGA ) said on Wednesday the U.S. Food and Drug Administration had cleared its Cortera Spinal Fixation System.
- ( SRGA ) stock is trading 7.4% higher premarket.
- The Cortera system is designed for spinal surgeries and will be used with the company’s HOLO Portal surgical guidance.
- The Company plans to add implants and instruments to the Cortera system over the next 3-4 years to expand into a majority of posterior fixation spinal procedures.
- The Cortera Spinal Fixation System limited market release is expected to positively contribute to Q4 results.
For further details see:
Surgalign stock rises 7% after receiving FDA clearance of Cortera spinal fixation system